Business Wire

CO-CSG

23.1.2024 14:31:29 CET | Business Wire | Press release

Share
CSG Earns Recognition from Leading Analyst Firms

Communication service providers (CSPs) are racing to modernize their operations and deliver dynamic and personalized experiences for their customers. To leverage automation, intelligence and orchestration, they’re working to improve the customer experience across all touchpoints. In 2023, CSG® (NASDAQ: CSGS)’s award-winning solutions and integrated omnichannel approach helped global brands transform their customer experience, earning CSG recognition from leading analyst firms Gartner, Frost & Sullivan, Kaleido Intelligence, MGI and Quadrant Knowledge Solutions.

In recent months, CSG has been recognized as:

  • A Niche player in the 2023 Gartner® Magic Quadrant™ for Configure, Price and Quote Application Suites
    • CSG Quote & Order enables CSPs to configure products with live pricing, creating comprehensive orders that seamlessly flow from quotes to fulfillment. An API-powered CPQ solution built for complex B2B services, it provides CSPs with the composability and order management capabilities they need to drive faster time to revenue and deliver a better overall customer experience.
  • A Leader in the 2023 Frost Radar for 5G Revenue Management and Monetization
    • CSG enables CSPs to reduce reliance on multi-vendor solutions, lowering time to market and total cost of ownership by integrating charging, billing, policy control and interconnect. The depth of its capability portfolio, modular SaaS platforms and unique partnership-driven approach earn CSG a leadership placement for its ability to monetize a variety of 5G use cases on a single SaaS platform.
    • Frost & Sullivan writes: "CSG has proven how it can integrate assets from a network and a messaging portfolio to provide a one-stop shop for CSPs. The company has mastered the challenges of hybrid operations."
  • A Leader in the 2023 MGI 360 Rating: The Agile Billing Top 50 Buyers Guide
    • MGI recognized CSG Ascendon as “a good fit for organizations looking to create modern monetization capability to support new business initiatives”. The report states: "CSG Ascendon represents a multi-tenant SaaS approach to monetization tools for B2C-oriented digital services. It has a sophisticated product catalog capability, can support customer and product hierarchies and abstract complex pricing methods, including usage."
  • A Champion in the 2023 Kaleido Intelligence Roaming Vendor Hub – Clearing & Settlement
    • CSG Retail Roaming Management platform enables CSPs to build new dynamic digital wholesale services and to drive the associated business models over 4G and 5G networks of any size. Kaleido notes: The CSG platform is "agile and extensible, bringing significant new functionality with minimal disruption to existing infrastructure."
    • CSG was also recognized as a High-Flyer in the Roaming Analytics & VAS and Fraud Management rating categories.
  • A Leader in the 2023 SPARK Matrix: Configure, Price & Quote
    • CSG Quote & Order helps service providers deliver complex digital offerings by addressing the dual challenges of B2B2X relationships with customers and partners. Its comprehensive capabilities, impressive customer references, well-defined roadmap and vision and a highly scalable product suit earn CSG strong ratings for technological excellence and customer impact.
    • Quadrant Knowledge Solutions notes: "CSG offers a leading CPQ portfolio, customized specifically for the telecom industry, apart from also having strong third-party partnerships, robust functional capabilities and an extensive customer base."

Beyond these recognitions, CSG is mentioned in the 2023 Gartner Market Guide for CSP Customer Management and Experience Solutions, which CIOs can use to shape their sourcing strategy by understanding the investments and directions of representative vendors. CSG was also mentioned in the 2022 Gartner Market Guide for Revenue Management and Monetization as one of 20 vendors providing a wide variety of solutions, offering different portfolios, deployment/implementation approaches and focus areas for various segments of CSPs.

“Global operators trust CSG to modernize their business because we've demonstrated time and again that we understand their customers’ needs and provide the capabilities they need to drive tangible growth,” said Chad Dunavant, Chief Product & Strategy Officer, CSG. “The breadth and depth of our portfolio support CSPs regardless of their focus on B2C, B2B or B2B2X as we empower them to deliver new services faster than competitors, increase customer satisfaction and boost brand loyalty. This has been our bread and butter for 40+ years and is why industry analysts consistently rank CSG among the leading BSS solution providers across the industry.”

For more information about CSG, visit www.csgi.com.

Gartner, Magic Quadrant for Configure, Price and Quote Application Suites, Mark Lewis, Dayna Radbill, 11 December 2023.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About CSG

CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.

Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123732657/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye